1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. AUTOMATED AND CLOSED SELL THERAPY MARKET BY THERAPY TYPE
5.1. Introduction
5.2. Stem-Cell Therapy
5.3. Non-Stem-Cell Therapy
6. AUTOMATED AND CLOSED SELL THERAPY MARKET BY SCALE
6.1. Introduction
6.2. Pre-Commercial / R&D Scale
6.3. Commercial Scale
7. AUTOMATED AND CLOSED SELL THERAPY MARKET BY END-USER
7.1. Introduction
7.2. Pharmaceuticals & Bio-Tech Companies
7.3. Research & Academic Institute
7.4. Others
8. AUTOMATED AND CLOSED SELL THERAPY MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Israel
8.5.4. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Miltenyi Biotec
10.2. Lonza
10.3. Fresenius Kabi
10.4. Danaher Corporation
10.5. BioSpherix, LLC
10.6. Terumo Corporation
10.7. Sartorius AG
10.8. ThermoGenesis
10.9. Cellares Inc.
10.10. Thermo Fisher Scientific, Inc.
10.11. Merck KgaA
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES